FDA NDC Directory · JSON-LD · Markdown

ATORVALIQ

NDC 46287-030 · HUMAN PRESCRIPTION DRUG · SUSPENSION

Labeler / ManufacturerCMP Pharma, Inc.
Marketing categoryNew Drug Application (innovator) · App NDA213260
Dosage form / routeSUSPENSION · ORAL
Active ingredientsATORVASTATIN CALCIUM TRIHYDRATE (20 mg/5mL)
Marketing started20230301
Package count1

External sources

Source: openFDA. Public-domain (CC0).